Skip to main navigation Skip to search Skip to main content

Effect of Montelukast on Time-Course of Exhaled Nitric Oxide in Asthma: Influence of LTC4 Synthase A-444C Polymorphism

  • Glenn J. Whelan
  • , Kathryn Blake
  • , Niranjan Kissoon
  • , Laurie J. Duckworth
  • , Jainwei Wang
  • , James E. Sylvester
  • , John J. Lima
  • Alfred I. duPont Hospital for Children
  • National Jewish Medical and Research Center
  • University of Florida

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

Leukotrienes (LT) mediate inflammation in asthma. The fraction of exhaled nitric oxide (FENO) is thought to be a sensitive and reproducible method for assessing airway inflammation in asthmatics and the anti-inflammatory effects of drugs. A number of factors are known to contribute to intrapatient variation in FENO which can confound interpretation. The aims of this study were to characterize the time-course of FENO, determine the effect of montelukast on the time-course of FENO, and evaluate the influence of the LTC4 synthase A-444C polymorphism on montelukast-evoked changes in FENO. Following a 2-week run-in, 7 males and 5 females with asthma, 10-16 years old, received 5 or 10 mg of montelukast or an identical placebo at bedtime for 7 days in double-blind, crossover fashion, followed by a 7-day washout. FENO was quantified every 30 min for 3 or 6 hr at baseline and on days 1, 2, 3, and 7 of treatment. A time-averaged value for FENO was calculated (FENO*), and % changes in FENO* relative to baseline vs. time following placebo and montelukast were compared. The genotype of the A-444C polymorphism was determined by PCR and RFLP. FE NO varied markedly as a function of time in each patient. Time-averaged values of FENO (FENO*) during placebo and montelukast treatment were similar. Montelukast significantly reduced the slope of the % change in FENO* vs. time curve in heterozygotes (n = 4), but not in A/A homozygotes (n = 8). These data suggest that heterozygotes respond better to montelukast compared to A/A homozygotes, at least with respect to changes in FENO. We conclude that assessment of inflammation or the anti-inflammatory effects of drugs in asthma based on single determinations of FENO can be misleading. We further conclude that the A-444C polymorphism in the LTC4 synthase gene probably contributes to interpatient variability in montelukast-evoked changes in FENO* and warrants further study.

Original languageEnglish
Pages (from-to)413-420
Number of pages8
JournalPediatric Pulmonology
Volume36
Issue number5
DOIs
StatePublished - Nov 2003
Externally publishedYes

Keywords

  • Asthma
  • Exhaled nitric oxide
  • Montelukast
  • Polymorphism

Fingerprint

Dive into the research topics of 'Effect of Montelukast on Time-Course of Exhaled Nitric Oxide in Asthma: Influence of LTC4 Synthase A-444C Polymorphism'. Together they form a unique fingerprint.

Cite this